PPGN — PolyPeptide AG Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMid CapMomentum Trap

Annual cashflow statement for PolyPeptide AG, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.

	2019 December 31st	C2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	25.7	31.3	47.3	7.77	-51.4
Depreciation
Non-Cash Items	7.81	13.7	22.7	6.83	16.7
Unusual Items
Other Non-Cash Items
Changes in Working Capital	6.24	-13.1	-33.3	-35.2	40.7
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	55.6	49.5	57.4	5.46	36.5
Capital Expenditures	-19.7	-43.2	-77.7	-78.8	-56.7
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	7.44	0.641	-3.14	0.329	-2.78
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-12.3	-42.6	-80.8	-78.4	-59.5
Financing Cash Flow Items	—	0	-4.38	0	—
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-35.9	-6.73	131	-26.9	84.5
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	7.47	-0.3	119	-98.8	58.2